Effects of Complement Regulators and Chemokine Receptors in Type 2 Diabetes

References

• Alegretti AP, Mucenic T, Merzoni J, Faulhaber GA, Silla LM, Xavier RM. 2010. Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus [SLE] patients. Cell Immunol. 265:478–491.
   Web of Science ®Google Scholar
• American Diabetes Association. 2011. Diagnosis and classification of diabetes mellitus. Diabetes Care. 34:62–69.
   PubMed Web of Science ®Google Scholar
• Barcellos LF, Schito AM, Rimmler JB, Vittinghoff E, Shih a, Lincoln R, Callier S, Elkins MK, Goodkin DE, Haines JL, et al. 2000. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics. 51(4–5):281–88.
   PubMed Web of Science ®Google Scholar
• Collard CD, Väkevä a, Morrissey MA, Agah a, Rollins SA, Reenstra WR, Buras JA, Meri S, Stahl GL. 2000. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol. 156:1549–56.
   PubMed Web of Science ®Google Scholar
• De Oliveire KB, Guembarovski RL, Oda JM, Mantovani MS, Carrera CM, Reiche EM, Voltarelli JC, Do Amaral ACDS, Watanabe MA. 2011. CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients. Cytokine. 55:260–65.
   PubMed Web of Science ®Google Scholar
• Dubois-Laforgue D, Hendel H, Caillat-Zucman S, Zagury JF, Winkler C, Boitard C, Timsit J. 2001. A common stromal cell-derived factor-1 chemokine gene variant is associated with the early onset of type 1 diabetes. Diabetes. 50:1211–13.
   PubMed Web of Science ®Google Scholar
• Egan CG, Lavery R, Caporali F, Fondelli C, Laghi-Pasini F, Dotta F, Sorrentino V. 2008. Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia. 51:1296–305.
   PubMed Web of Science ®Google Scholar
• García-Valladares I, Atisha-Fregoso Y, Richaud-Patin Y, Jakez-Ocampo J, Soto-Vega E, Elías-López D, Carrillo-Maravilla E, Cabiedes J, Ruiz-Argüelles a, Llorente L. 2006. Diminished expression of complement regulatory proteins [CD55 and CD59] in lymphocytes from systemic lupus erythematosus patients with lymphopenia. Lupus. 15:600–05.
   PubMed Web of Science ®Google Scholar
• Ide a, Kawasaki E, Abiru N, Sun F, Fukushima T, Takahashi R, Kuwahara H, Fujita N, Kita a, Oshima K, et al. 2003. Stromal-cell derived factor-1 chemokine gene variant is associated with type 1 diabetes age at onset in Japanese population. Hum Immunol. 64:973–78.
   PubMed Web of Science ®Google Scholar
• Kim DD, Song WC. 2005. Membrane complement regulatory proteins. Clin Immunol. 118:127–36.
   PubMed Web of Science ®Google Scholar
• King GL. 2008. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 79:1527–34.
   PubMed Web of Science ®Google Scholar
• King GL, Loeken MR. 2004. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol. 122:333–38.
   PubMed Web of Science ®Google Scholar
• Kostic N, Caparevic Z, Marina D, Ilić S, Radojković J, Cosić Z, Bakic-Celic V. 2009. Clinical evaluation of oxidative stress in patients with diabetes mellitus type 2-impact of acute exercise. Vojnosanit Pregl. 66:459–64.
   PubMed Web of Science ®Google Scholar
• Lee JP, Bae JB, Yang SH, Cha RH, Seong EY, Park YJ, Ha J, Park MH, Paik JH, Kim YS. 2011a. Genetic predisposition of donors affects the allograft outcome in kidney transplantation; polymorphisms of stromal-derived factor-1 and CXC receptor 4. PLoS One. 6:e16710.
   PubMed Web of Science ®Google Scholar
• Lee YL, Kuo WH, Lin CW, Cheng WE, Chen SC, Shih CM. 2011b. Association of genetic polymorphisms of CXCL12/SDF1 gene and its receptor, CXCR4, to the susceptibility and prognosis of non-small cell lung cancer. Lung Cancer. 73:147–52.
   PubMed Web of Science ®Google Scholar
• Lin Y, Sun Z. 2010. Current views on type 2 diabetes. J Endocrinol. 204:1–11.
   PubMed Web of Science ®Google Scholar
• Ma XW, Chang ZW, Qin MZ, Sun Y, Huang HL, He Y. 2009. Decreased expression of complement regulatory proteins, CD55 and CD59, on peripheral blood leucocytes in patients with type 2 diabetes and macrovascular diseases. Chin Med J [Engl]. 122:2123–28.
   PubMed Web of Science ®Google Scholar
• Malecki MT. 2005. Genetics of type 2 diabetes mellitus. Diabetes Res Clin Pract. 68:10–21.
   PubMed Web of Science ®Google Scholar
• Matin K, Salam MA, Akhter J, Hanada N, Senpuku H. 2002. Role of stromal-cell derived factor-1 in the development of autoimmune diseases in non-obese diabetic mice. Immunology. 107:222–32.
   PubMed Web of Science ®Google Scholar
• Ratajczak MZ, Majka M, Kucia M, Drukala J, Pietrzkowski Z, Peiper S, Janowska-Wieczorek a. 2003. Expression of functional CXCR4 by muscle satellite cells and secretion of SDF-1 by muscle-derived fibroblasts is associated with the presence of both muscle progenitors in bone marrow and hematopoietic stem/progenitor cells in muscles. Stem Cells. 21:363–71.
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles a, Llorente L. 2007. The role of complement regulatory proteins [CD55 and CD59] in the pathogenesis of autoimmune hemocytopenias. Autoimmun Rev. 6:155–61.
   PubMed Web of Science ®Google Scholar
• Styskal J, Van Remmen H, Richardson a, Salmon AB. 2012. Oxidative stress and diabetes: what can we learn about insulin resistance from antioxidant mutant mouse models? Free Radic Biol Med. 52:46–58.
   PubMed Web of Science ®Google Scholar
• Teng YH, Liu TH, Tseng HC, Chung TT, Yeh CM, Li YC, Ou YH, Lin LY, Tsai HT, Yang SF. 2009. Contribution of genetic polymorphisms of stromal cell-derived factor-1 and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. Head Neck. 31:1282–88.
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, Mc Geer EG, Mc Geer PL. 2001. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 21:1214–19.
   PubMed Web of Science ®Google Scholar
• Zhang J, Gerhardinger C, Lorenzi M. 2002. Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes. 51:3499–504.
   PubMed Web of Science ®Google Scholar
• Zimmet P, Alberti KG, Shaw J. 2001. Global and societal implications of the diabetes epidemic. Nature. 414:782–87.
   PubMed Web of Science ®Google Scholar